A vaccine aimed at preventing pancreatic cancer in people at high risk was reported to be safe and capable of generating durable immune responses, according to findings highlighted by the American Association for Cancer Research. The update points to a potential new strategy focused on prevention rather than treatment after cancer develops.

After a median follow-up of 16.5 months, none of the participants had developed pancreatic cancer. Researchers also reported that some precancerous lesions became smaller or stopped growing during that period, adding to the early signs that the approach may be having a biological effect.

The results are notable because they suggest a preventive pancreatic cancer vaccine could help high-risk individuals before invasive disease appears. The mention of durable immune responses indicates the vaccine was able to maintain an immune reaction over time, an important feature for any prevention-based approach.

Even so, these findings reflect an early follow-up window. Longer observation and further research will be needed to understand how lasting the protection may be and how the vaccine performs in broader groups of high-risk patients.